IL17A and uveitis: Retinal toxicity derived from anti-IL-17 antibody treatments has not been previously reported in other murine uveitis models [34,46,47], indicating that the toxicity could possibly involve a combination of events within this particular disease model, such as glial cell activation within the retina, the presence of PG-antigen within the retina, and/or ongoing systemic disease [4].